Get started

Biotechnology

Solid Biosciences Announces $90 Million Private PlacementSolid Biosciences Announces $90 Million Private Placement Solid Biosciences has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $90 million private placement, which is expected to close on or about December 15, 2020, subject to the satisfaction of customary closing conditions. The private placement includes new investors Suvretta Capital Management, LLC and Aspire Capital Fund, LLC and existing investors, including RA Capital Management, Perceptive Advisors, LLC, Bain Capital Life Sciences, EcoR1 Capital, LLC, Boxer Capital, and Ikarian Capital, LLC, as well as certain board members and executive officers. In this private placement, the Company is selling 24,324,320 shares of common stock at a price of $3.70 per share. The Company expects to use net proceeds from the private placement to fund research and development expenses, including the advancement of SGT-001, and for working capital and other general corporate purposes. finance.yahoo.com
NASDAQ:SLDB
by AlenCiken
BCRX - keep trading the pullbackNote from BoA Global Research: "BCRX announced a royalty purchase agreement with RPRX and a credit loan agreement with Athyrium. BCRX will receive an upfront $125mn cash from RPRX, in exchange for 8.75% sales-based royalties up to $350mn annual sales, 2.75% royalties between $350mn-$550mn and tiered revenues outside of key territories for the recently-approved Orladeyo in preventing hereditary angioedema (HAE) attacks. The agreement also grants RPRX 1% sales royalty on its oral Factor D inhibitor BCX9930 that’s currently being evaluated in treating paroxysmal nocturnal hemoglobinuria (PNH). BCRX will also draw $125mn from the $200mn credit facility with Athyrium to repay outstanding ~$44mn debt with MidCap Fin. Trust and support its ongoing launch of Orladeyo and R&D development. We positively view today’s updates, as the agreements strengthen the company’s balance sheet and remove the near term need for dilutive financing. It also extends its cash runway meaningfully and allows the company to focus on advancing the early-stage BCX9930 program."
NASDAQ:BCRXLong
by KhanhC.Hoang
1
Buy Signal: 13.04Ingenuity Trading Model used in- Stock, Forex, Futures, and Crypto markets. For Stops and overall trade management join the club. The model is a Geometric Markov Model : In probability theory, a Markov model is a stochastic model used to predict randomly changing systems. Markov Models are used in all aspects of life from Google search to daily weather forecast. The randomly changing systems we focus on are the equity, futures, and forex markets. The geometric element of the model is the fractal wave structure you can find on any chart you look at across any market and across all time dimensions. Our model focuses on the current wave formation (current state)- geometric price formation along with its volume and volatility over a given time period and using that information to predict the future state- future price movement. For questions or more information feel free to contact me in the comment section or via private chat
NASDAQ:CGENLong
by IngenuityTrading
Ascending Triangle breakout for TRIL?It appears as though TRIL is breaking the horizontal resistance of the ascending triangle, only modestly at the time being. The two green lines are the shoulders of an Inverted Head & Shoulders, and the blue head is obviously the head of the pattern. On the RSI there's a bullish flag or descending triangle forming, I guess we will see if there's enough momentum to break through the downward sloping resistance, and possibly back test turning into support like I have drawn hypothetically in green. A bearish cross already happened on the KST, it looks like a bullish cross is on the horizon. Clearly a divergence between the price rising and the RSI moving moderately sideways.
TLong
by ScotianBot
BioNTech delivers like promised | NEW COVID VACCINE DATA | Hey fellow Traders! Today From MAINZ, Germany to NEW YORK . In the last Analysis we talked about upside potential of the freshly developed Covid-19 Vacccine from NASDAQ:BNTX and NYSE:PFE Also calling out those huge gains even before all those news were released. "Today those companies announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study. After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases." This means we are right on track for the FDA Fast Track Drug Approval, on which the whole world put their hopes on. With increasing daily cases this news are like a rescue ring in the middle of the ocean. But lets get back to the chart. We had a huge upper resistance level at the psychological mark at $100 but if this move today turns out to not just be a bull trap and we can see a solid consolidation phase, im optimistic to see a new support level building up at the prior resistance. As we can see the uptrend is still intact and we could form a nice resistance/support level over time. With the incoming cataclyst it should be pretty obvious that we are likely to see a evven stronger upmove soon. But this stock is still a playball from big hegdefonds and investors. So be careful when trading this. Personally i´ll use the next the next rebound to stock up, wait for the news and then sell nearly all those shares on good news. Why i am sure about this? - Well the stock had the same moves for the past months, and if you understoof this, it was like a money making machine. - First come first served - Millions of pre sold Vaccine doses to dozen of countries. - Momentum - No insider sold yet - MRNA TECHNOLOGY - CANCER MEDICICNE IN THE PIPELINE - Incredible Management Team - And of course Everyone wants to finally get their old life back. - $1.4 B Potential Revenue - Bill Gates Thank you for taking your time to read this. I hope this was interesting and useful to you. Best greetings and happy trading! :) Disclaimer: All writers opinions are their own and dod not constitute financial advise in any way whatsovver. Nothing published by me constitutes an investment recoomenddation, nor should any data or Content be relied upon for any investment activites. I strongly recommend that you perfom your own independdet research and/or speak with a qualified investment professional before making any financial decisions.
NASDAQ:BNTXLong
by Sebastian-TradingExpertsEU
2
Healthcare Critical LevelTechnical Analysis The 200ema has been tested several times, and has worked very well as a mid-term support level. Risk reward ratio is easy to set-up with a 3:1 ratio approximately. Sector & Industry Analysis It is important to note that the industries inside the sector have different performance, which has been very useful to analyze what the market thinks of the risk of healthcare with the election coming up. The following list is the Healthcare Industries with a 6-month performance % move, as well as a some good ETF to follow/trade: Healthcare Technology --> +56% // have not found appropriate ETF. Biotechnology --> +21% // XBI (smaller biotech), IBB (large-cap biotech), ARKG (genomics) Healthcare Equipment --> +19% // IHI Healthcare Providers --> +5.51% // IHF Pharmaceuticals --> -1.3% // IHE
AMEX:XLV
by dorfmanmaster
ALRN Weekend Data CatalystALRN had some weekend news. Will be interesting to see if it can break above a near-two-year resistance level. I didn't show it all the way back to November of 2018 but if you take the chart out further, you can see this level holding as resistance. "Saturday, the company announced new positive clinical data from its ongoing Phase 1b trial. The trial demonstrated clinical proof of concept that treatment with ALRN-6924 prior to second-line topotecan administration resulted in a protective effect against severe anemia, thrombocytopenia and neutropenia. This was in patients with p53-mutated small cell lung cancer. The results were featured in a late-breaking poster presentation entitled, 'Prevention of Chemotherapy-induced Myelosuppression in SCLC Patients Treated with Dual MDM2/MDMX Inhibitor ALRN-6924.'" Original Quote Source: 5 Penny Stocks On Robinhood To Buy Under $2; Are They Too Risky?
A
by PennyStocks101
MGEN Done Going Down Or Just A Pit Stop?MGEN has been getting hammered lately. Not one single green close in the last few weeks. Friday was the first, somewhat green close and that ain't saying much. But trading action was interesting. "riday’s action was something much different than what the penny stock had seen during the 2 weeks prior. It was the first trading day that MGEN shares didn’t close red. If you look at the chart, since October 9th, the penny stock saw a red close every day...Furthermore, trading action continued to push shares higher during after-hours on Friday." Original Quote Source: 5 Penny Stocks On Robinhood To Buy Under $2; Are They Too Risky?
M
by PennyStocks101
Make or Break Week For AXGT?AXGT is back at another area of support/resistance. Friday will be another day to keep in mind in light of the company's event. There will be additional data and program updates at its Parkinson’s disease R&D Day on Friday. Remember what was also said originally with this particular trial “These data, showing over 20 points of improvement on the UPDRS Part III ‘OFF’ motor function score, as well as meaningful improvements in quality of life measures, underscores the potentially best-in-class profile of AXO-Lenti-PD gene therapy in Parkinson’s disease. The totality of data seen thus far reinforces my belief that AXO-Lenti-PD has the potential to transform the treatment of patients with Parkinson’s disease through one-time administration of gene therapy.” - Gavin Corcoran, M.D., Chief R&D Officer at Axovant. Original Quote Source: 5 Biotech Penny Stocks To Watch With Recent & Upcoming Events
A
by PennyStocks101
High Traffic Pivots on CASI ChartCASI saw a nice bump in after-hours trading Friday. Shares hit $1.88. Can the Oppenheimer analyst rating be enough of a catalyst to carry through this momentum into the week ahead is the biggest question. Great volume on Friday but is it all for nothing? "What had sparked some excitement came in light of new analyst activity. Oppenheimer analyst Leland Gershell initiated coverage on CASI. The analyst gave it an Outperform rating and announced a price target of $5. That represents a 182% premium to Friday’s closing price for CASI stock." Original Quote Source: 5 Biotech Penny Stocks To Watch With Recent & Upcoming Events
NASDAQ:CASI
by PennyStocks101
Biotech etf catching up to the Qstested recently pitchfork upper line and bounced off..bullish sign. depending on timeframe but for this one BBC is catching up to the Qs. short term it looks just as over-exteneded as the Qs. trading will get very choppy short term. Disclaimer, this is only for entertainment and education purposes and doesn't serve by any means as a buy or sell recommendation. Personally I hold both long term long positions and occasionally short term short position, for disclosure purpose.
AMEX:BBC
by hanzhao311
2